Xuefu Zhuyu Capsule alleviates depression in post-stroke depression model rats <i>via</i> modulation of the gut microbiota–gut–brain axis

Xuefu Zhuyu Capsule (XFZY) demonstrated potential in alleviating post-stroke depression (PSD), a condition whose underlying mechanisms may involve the gut-brain axis. This study aimed to explore the therapeutic effects of XFZY on PSD and its possible modulation of the gut microbiota-gut-brain axis in a rat model. Wistar rats were randomly assigned to sham, PSD, three XFZY dose (0.216, 0.432, 0.864 g/kg), and fluoxetine (1.80 mg/kg) groups (n = 12 per group). The PSD model was established using transient middle cerebral artery occlusion (t-MCAO) combined with chronic unpredictable mild stress (CUMS), followed by 28 days of XFZY administration. In a separate experiment, gut microbiota was depleted via antibiotic cocktails, with rats divided into sham, PSD, XFZY medium Dose (XFM), pseudo-germ-free (PGF) and PGF + XFM (PGFX) groups. Behavioral tests indicated that XFZY ameliorated depressive-like behaviors, with the medium dose (0.432 g/kg) showing the most significant effect. Histological analysis using hematoxylin and eosin (H&E) and Nissl staining revealed that XFZY alleviated colonic and neuronal damage. Furthermore, 16S rRNA sequencing and gas chromatography revealed that XFZY modulated gut microbiota composition, increased species richness, and elevated levels of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid. Enzyme-Linked Immunosorbent Assay (ELISA) results showed that XFZY reduced pro-inflammatory cytokines - interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), while immunohistochemistry indicated enhanced intestinal barrier function and reduced neuroinflammation. Furthermore, after depletion of gut microbiota using antibiotic cocktails, these therapeutic effects of XFZY were abolished. In summary, XFZY may alleviate PSD by modulating the gut microbiota and regulating the gut-brain axis, offering a promising direction for future therapeutic research.

Authors

Institutions

Publication Details

Journal
Drug Discoveries & Therapeutics
Published
2026-02-12
DOI
https://doi.org/10.5582/ddt.2025.01120
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Xuefu Zhuyu Capsule alleviates depression in post-stroke depression model rats via modulation of the gut microbiota–gut–brain axis

Xuejin Fan, Bowen Jin, Y. Wang, Yanjun Zhang et al.
Drug Discoveries & Therapeutics
Gut microbiota and health
article

Xuefu Zhuyu Capsule alleviates depression in post-stroke depression model rats via modulation of the gut microbiota–gut–brain axis

Xuejin Fan, Bowen Jin, Y. Wang, Yanjun Zhang, Pengwei Zhuang, Zhaowei Zhang
article en

Abstract

Xuefu Zhuyu Capsule (XFZY) demonstrated potential in alleviating post-stroke depression (PSD), a condition whose underlying mechanisms may involve the gut-brain axis. This study aimed to explore the therapeutic effects of XFZY on PSD and its possible modulation of the gut microbiota-gut-brain axis in a rat model. Wistar rats were randomly assigned to sham, PSD, three XFZY dose (0.216, 0.432, 0.864 g/kg), and fluoxetine (1.80 mg/kg) groups (n = 12 per group). The PSD model was established using transient middle cerebral artery occlusion (t-MCAO) combined with chronic unpredictable mild stress (CUMS), followed by 28 days of XFZY administration. In a separate experiment, gut microbiota was depleted via antibiotic cocktails, with rats divided into sham, PSD, XFZY medium Dose (XFM), pseudo-germ-free (PGF) and PGF + XFM (PGFX) groups. Behavioral tests indicated that XFZY ameliorated depressive-like behaviors, with the medium dose (0.432 g/kg) showing the most significant effect. Histological analysis using hematoxylin and eosin (H&E) and Nissl staining revealed that XFZY alleviated colonic and neuronal damage. Furthermore, 16S rRNA sequencing and gas chromatography revealed that XFZY modulated gut microbiota composition, increased species richness, and elevated levels of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid. Enzyme-Linked Immunosorbent Assay (ELISA) results showed that XFZY reduced pro-inflammatory cytokines - interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), while immunohistochemistry indicated enhanced intestinal barrier function and reduced neuroinflammation. Furthermore, after depletion of gut microbiota using antibiotic cocktails, these therapeutic effects of XFZY were abolished. In summary, XFZY may alleviate PSD by modulating the gut microbiota and regulating the gut-brain axis, offering a promising direction for future therapeutic research.

Drug Discoveries & TherapeuticsVol. 20(1)
Tianjin University of Traditional Chinese Medicine (CN), First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (CN)
Openalex Percentile: Top 58%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.